Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma

Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news